Duvelisib, dual inhibitor of PI3K delta and PI3K gamma, for indolent non-Hodgkin lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Ian Flinn, MD, of Tennessee Oncology, Nashville, TN, discusses the clinical development of duvelisib, a dual inhibitor of phosphoinositide 3-kinase (PI3K) delta and PI3K gamma, for the treatment of patients with indolent non-Hodgkin lymphoma (iNHL). Duvelisib has demonstrated promising clinical activity in patients with relapsed/refractory iNHL and ongoing clinical trials are investigating duvelisib alone and in combination for this disease.

Share this video